Targeting mTOR and survivin concurrently potentiates radiation therapy in renal cell carcinoma by suppressing DNA damage repair and amplifying mitotic catastrophe
Abstract Background Renal cell carcinoma (RCC) was historically considered to be less responsive to radiation therapy (RT) compared to other cancer indications. However, advancements in precision high-dose radiation delivery through single-fraction and multi-fraction stereotactic ablative radiothera...
Сохранить в:
| Главные авторы: | , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BMC
2024-06-01
|
| Серии: | Journal of Experimental & Clinical Cancer Research |
| Предметы: | |
| Online-ссылка: | https://doi.org/10.1186/s13046-024-03079-8 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|